Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Bamlanivimab/etesevimab  COVID-19 treatment studies for Bamlaniv../e..  C19 studies: Bamlaniv../e..  Bamlaniv../e..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 0% Improvement Relative Risk Hospitalization -4% Hospitalization/ER -5% Priest et al. Bamlanivimab/e.. for COVID-19 LATE Is late treatment with bamlanivimab/etesevimab beneficial for COVID-19? PSM retrospective 758 patients in the USA (October 2020 - March 2021) No significant difference in outcomes seen Priest et al., Infectious Diseases in Clinical P.., doi:10.1097/IPC.0000000000001130 Favors bamlanivimab/e.. Favors control
Bamlanivimab for the Prevention of Hospitalizations and Emergency Department Visits in SARS-CoV-2–Positive Patients in a Regional Health Care System
Priest et al., Infectious Diseases in Clinical Practice, doi:10.1097/IPC.0000000000001130
Priest et al., Bamlanivimab for the Prevention of Hospitalizations and Emergency Department Visits in SARS-CoV-2–Positive.., Infectious Diseases in Clinical Practice, doi:10.1097/IPC.0000000000001130
Jan 2022   Source   PDF  
  All Studies   Meta
Retrospective 379 bamlanivimab patients and 379 matched controls in the USA, showing no significant differences with treatment.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, VanBlargan].
risk of death, no change, RR 1.00, p = 1.00, treatment 6 of 379 (1.6%), control 6 of 379 (1.6%).
risk of hospitalization, 3.9% higher, RR 1.04, p = 0.86, treatment 79 of 379 (20.8%), control 76 of 379 (20.1%), all-cause hospital revisit.
risk of hospitalization/ER, 5.0% higher, OR 1.05, p = 0.86, treatment 379, control 379, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Priest et al., 27 Jan 2022, retrospective, propensity score matching, USA, peer-reviewed, 5 authors, study period October 2020 - March 2021, average treatment delay 6.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBamlaniv../e..All
Abstract: ORIGINAL ARTICLE Bamlanivimab for the Prevention of Hospitalizations and Emergency Department Visits in SARS-CoV-2–Positive Patients in a Regional Health Care System David H. Priest, MD, MPH,* Lisa M. Blanchette, PharmD, MHA,† Aliza L. Hekman, MMS, PA-C,* Rahul Maddikunta, MS,* and Paula E. Burleson, BSBA* Introduction: Bamlanivimab (LY-CoV555) was approved by Emergency Use Authorization by the United States Food and Drug Administration in the ambulatory setting to prevent hospitalizations and emergency department visits. We report a retrospective, case-control study of bamlanivimab use in a regional health care system. Methods: A retrospective case-control study for SARS-CoV-2–positive patients receiving bamlanivimab and matched controls between October 2020 and March 2021 was performed. End points included all-cause hospitalization, emergency department visits, and mortality. Results: No statistically significant difference was noted in all-cause hospitalization, emergency department visits, or mortality, including patients 65 years or older, body mass index of 35 or higher, diagnosis of diabetes mellitus, or cancer (high-risk patients). No difference was seen based on timing of bamlanivimab infusion relative to symptom onset or timing of infusion within the study period. Conclusions: Based on the evaluated endpoints, there was no benefit from bamlanivimab, regardless of when it was received in a patient's clinical course or when during the study period it was received. A lack of efficacy of monoclonal antibodies in patients infected with COVID-19 variants has been noted, but the impact of local variants on these results could not be assessed given a lack of available variant diagnostic tools. These findings do not support bamlanivimab for the prevention of hospitalization or emergency department visits for patients with mild to moderate SARS-CoV2 infection. Key Words: SARS-CoV-2, COVID-19, bamlanivimab, monoclonal antibody (Infect Dis Clin Pract 2022;30: e1130) T he COVID-19 pandemic caused by SARS-CoV-2 has had a devastating impact on the health of communities around the world, as well as the global economy.1,2 In response, several therapeutic interventions have been developed and evaluated, including virus neutralizing monoclonal antibodies.3,4 These antibodies are isolated from the blood of recovered patients after infection with SARS-CoV-2 and offer passive immunity to those receiving the antibody therapies. One such agent is bamlanivimab (LYCoV555; Lilly), a recombinant, neutralizing monoclonal antibody developed by the US Vaccine Research Center at the National Institute of Allergy and Infectious Diseases and AbCellera From the *Novant Health Institute of Safety and Quality; †Novant Health Department of Pharmacy, Winston-Salem, NC. Correspondence to: David H. Priest, MD, MPH, Novant Health Institute of Safety and Quality, Suite 600, 101 North Cherry St, Winston-Salem, NC 27101. E‐mail: The authors have no funding or conflicts of interest to disclose. Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop